ShapeTX_logo_blue_1200x628.png
Shape Therapeutics Unveils Major Advances in AI-Powered Platform for Precision RNA Editing
October 03, 2024 13:05 ET | Shape Therapeutics, Inc.
Shape Therapeutics, a leader in RNA-based gene therapy, today released two preprint manuscripts detailing major technological breakthroughs.
ShapeTX_logo_blue_1200x628.png
Shape Therapeutics Appoints Healthcare Industry Leaders David Epstein and Todd Simpson to its Board of Directors
June 25, 2024 09:00 ET | Shape Therapeutics, Inc.
Shape Therapeutics Appoints Healthcare Industry Leaders David Epstein and Todd Simpson to its Board of Directors
ShapeTX_logo_blue_1200x628.png
Shape Therapeutics RNAfix® Editing Platform Achieves >90% Editing in Mouse and Non-Human Primate Brain
May 08, 2024 09:31 ET | Shape Therapeutics, Inc.
RNAfix achieves up to 92% editing in the non-human primate brain after AAV-based gRNA delivery RNAfix achieves >95% editing throughout the mouse brain with sustained durability at least 6 months...
ShapeTX_logo_blue_1200x628.png
Shape Therapeutics Announces Appointment of Matt Valentino as Chief People Officer
May 02, 2024 08:00 ET | Shape Therapeutics, Inc.
SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, is pleased to announce the...
ShapeTX_logo_blue_1200x628.png
Shape Therapeutics to Showcase RNA Editing in the Brain and Validation of their Stable AAV Producer Cell Line at ASGCT 2024
April 30, 2024 08:00 ET | Shape Therapeutics, Inc.
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics, a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, today announced its upcoming oral presentations...
ShapeTX_logo_blue_1200x628.png
ShapeTX Expands Strategic Collaboration with Roche with Addition of a New Target
November 30, 2023 08:00 ET | Shape Therapeutics, Inc.
ShapeTX announces the expansion of its drug discovery partnership with Roche with new target
ShapeTX_Logo_BLUE.png
Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases
September 07, 2023 17:00 ET | Shape Therapeutics, Inc.; Otsuka
TOKYO and SEATTLE, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Otsuka Pharmaceutical Co., Ltd. (Otsuka) and ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announce...
ShapeTX_Logo_BLUE.png
ShapeTX Announces the Appointment of Adrian W. Briggs, Ph.D. As Chief Technology Officer
June 20, 2023 08:00 ET | Shape Therapeutics, Inc.
SEATTLE, June 20, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announced the appointment of Adrian W. Briggs, Ph.D. as Chief...
ShapeTX_Logo_BLUE.png
ShapeTX Announces Seven Presentations at ASGCT 2023 Showcasing the Potential of Generative AI and RNA in CNS Disorders and Beyond
May 04, 2023 08:00 ET | Shape Therapeutics, Inc.
SEATTLE, May 04, 2023 (GLOBE NEWSWIRE) -- ShapeTX, the programmable medicine company using AI and RNA to end genetic diseases, today announced seven presentations from across its technology...
ShapeTX_Logo_BLUE.png
ShapeTX to Showcase Groundbreaking Advances in CNS in vivo RNA Editing, CNS-Targeting AAVs, and TruStable™ AAV Manufacturing at the J.P. Morgan 41st Annual Healthcare Conference
January 05, 2023 08:00 ET | Shape Therapeutics, Inc.
SEATTLE, Jan. 05, 2023 (GLOBE NEWSWIRE) -- ShapeTX today announced Francois Vigneault, Ph.D., Co-founder and Chief Executive Officer, will present at the J.P. Morgan 41st Annual Healthcare...